Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole in pediatric invasive aspergillosis
NCT04218851Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of posaconazole in invasive aspergillosis (IA), sponsored by Merck & Co.. Started Jul 2020; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT04218851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218851.